Citations

Mayo Clinic

Showing 10 of 108599 citations.

P885: SOLITARY PLASMACYTOMA: SINGLE INSTITUTION EXPERIENCE AND SYSTEMATIC REVIEW AND META-ANALYSIS OF CLINICAL OUTCOMES
Charalampous, Charalampos , Kapoor, Prashant , Fonder, Amie , Hayman, Suzanne R. , Hobbs, Miriam, Hwa, Yi L. , Kourelis, Taxiarchis , Lacy, Martha Q. , Warsame, Rahma , Kyle, Robert A. , Kumar, Shaji , Claveau, Jean‐Sébastien , Binder, Moritz , Buadi, Francis K. , Cook, Joselle , Dingli, David , Dispenzieri, Angela , Gertz, Morie A. , Gonsalves, Wilson I. , Leung, Nelson , Lin, Yi , Rajkumar, S. Vincent

HemaSphere | August 9, 2023 | Volume: 7 | Issue: S3 | Pages: e81981ce

10.1097/01.hs9.0000970444.81981.ce Get It

P866: IDECABTAGENE VICLEUCEL (IDE-CEL) VS STANDARD REGIMENS IN PATIENTS WITH TRIPLE-CLASS–EXPOSED (TCE) RELAPSED AND REFRACTORY MULTIPLE MYELOMA (RRMM): KARMMA-3 SUBGROUP ANALYSIS BY PRIOR LINES OF THERAPY
Manier, Salomon , Mateos, María‐Victoria , Munshi, Nikhil C. , Arnulf, Bertrand , Vij, Ravi , Broijl, Annemiek , Sborov, Douglas W. , Iida, Shinsuke , Truppel-Hartmann, Anna, Yang, Zhihong, Piasecki, Julia , Felten, Jasper, Caia, Andrea, Rodríguez‐Otero, Paula , Einsele, Hermann , Bahlis, Nizar Jacques , Ailawadhi, Sikander , Nooka, Ajay K. , Abrahamsen, Ingerid Weum , Jagannath, Sundar , Benjamin, Reuben , Gergis, Usama , Cook, Mark , Baz, Rachid

HemaSphere | August 9, 2023 | Volume: 7 | Issue: S3 | Pages: e3385948

10.1097/01.hs9.0000970368.33859.48 Get It

P915: TREATMENT PATTERNS AND CLINICAL OUTCOMES OF PATIENTS WITH MULTIPLE MYELOMA PREVIOUSLY TREATED WITH LENALIDOMIDE AND AN ANTI-CD38 MONOCLONAL ANTIBODY: FINDINGS FROM THE CONNECT MM DISEASE REGISTRY
Abonour, Rafat , Rifkin, Robert M. , Gasparetto, Christina, Durie, Brian G.M. , Terebelo, Howard R. , Narang, Mohit , Toomey, Kathleen, Tang, Yuexin , Dhanasiri, Sujith, Anand, Jasmeet, Yu, Edward, Marshall, Thomas, Liu, Liang , Ailawadhi, Sikander , Lee, Hans C. , Wagner, Lynne I. , Hardin, James W. , Jagannath, Sundar

HemaSphere | August 9, 2023 | Volume: 7 | Issue: S3 | Pages: e52503e2

10.1097/01.hs9.0000970564.52503.e2 Get It

P1152: DEPTH OF METABOLIC RESPONSE AT INTERIM PET AND SURVIVAL OUTCOMES AMONG PATIENTS WITH PRIMARY REFRACTORY OR EARLY RELAPSING DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL)
Bock, Allison M. , Mwangi, Raphael , Ataei, Fatemeh , Pritchett, Josh, Shreve, Jacob , Khurana, Arushi , Nowakowski, Grzegorz S. , Thorpe, Matthew , Maurer, Matthew J. , Paludo, Jonas , Cerhan, James R. , Witzig, Thomas E. , Habermann, Thomas M. , Wang, Yucai , Young, Jason R.

HemaSphere | August 9, 2023 | Volume: 7 | Issue: S3 | Pages: e6583552

10.1097/01.hs9.0000971504.65835.52 Get It

P903: CLINICAL UTILITY OF MONOCLONAL GAMMOPATHY SCREENING IN THE EVALUATION OF PERIPHERAL NEUROPATHY
Maberry, Mackenzie, Smith, Caleb J. , Go, Ronald S.

HemaSphere | August 9, 2023 | Volume: 7 | Issue: S3 | Pages: e65762dc

10.1097/01.hs9.0000970516.65762.dc Get It

P936: EXPLORING HETEROGENEITY IN TREATMENT PREFERENCES OF PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA IN THE UNITED STATES, UNITED KINGDOM, FRANCE, SPAIN, ITALY AND GERMANY
Popat, Rakesh , Kleinman, David , Perera, Sue, Gorsh, Boris , Mulnick, Sarah, Alicia, Oneill, Hanna, Maya, Molinari, Alexa , Gelhorn, Heather L. , Popat, Rakesh , Ailawadhi, Sikander , Thomas, Caitlin , Ross, Melissa

HemaSphere | August 9, 2023 | Volume: 7 | Issue: S3 | Pages: e989881c

10.1097/01.hs9.0000970648.98988.1c Get It

TotalSegmentator: A Gift to the Biomedical Imaging Community
Sebro, Ronnie , Mongan, John , Mongan, John

Radiology: Artificial Intelligence | August 9, 2023 | Volume: 5 | Issue: 5 | Pages: No page available

10.1148/ryai.230235 | PMID 37795136 Get It

Targeting BCL6 in Gastrointestinal Stromal Tumor Promotes p53-Mediated Apoptosis to Enhance the Antitumor Activity of Imatinib
Zhao, Fei , Jia, Jie , Ma, Xianxiong , Jiang, Qi , Zhang, Ruizhi , Li, Chengguo , Wang, Tao , Liu, Weizhen , Hao, Yalan , Tao, Kaixiong , Zhang, Peng , Zeng, Xiangyu , Zhao, Fei , Jia, Jie , Ma, Xianxiong , Jiang, Qi , Zhang, Ruizhi , Li, Chengguo , Wang, Tao , Liu, Weizhen , Hao, Yalan , Tao, Kaixiong , Lou, Zhenkun , Zhang, Peng , Zeng, Xiangyu , Lou, Zhenkun

Cancer Research | August 9, 2023 | Volume: 83 | Issue: 21 | Pages: 3624-3635

10.1158/0008-5472.can-23-0082 | PMID 37556508 Get It

Abstract Imatinib mesylate (IM) has revolutionized the treatment of gastrointestinal stromal tumor (GIST). However, most patients inevitably acquire IM resistance. Second- and third-line treatments exhibit modest clinical benefits with a median time to disease progression of 4 to 6 months, highlighting the urgency for novel therapeutic approaches. Here, we report that the expression of BCL6, a known oncogenic driver and transcriptional repressor, was significantly induced in GIST cells following IM treatment. Elevated BCL6 levels suppressed apoptosis and contributed to IM resistance. Mechanistically, BCL6 recruited SIRT1 to the TP53 promoter to modulate histone acetylation and transcriptionally repress TP53 expression. The reduction in p53 subsequently attenuated cell apoptosis and promoted tolerance of GIST cells to IM. Concordantly, treatment of GIST cells showing high BCL6 expression with a BCL6 inhibitor, BI-3802, conferred IM sensitivity. Furthermore, BI-3802 showed striking synergy with IM in IM-responsive and IM-resistant GIST cells in vitro and in vivo. Thus, these findings reveal a role for BCL6 in IM resistance and suggest that a combination of BCL6 inhibitors and IM could be a potentially effective treatment for GIST. Significance: BCL6 drives resistance to imatinib by inhibiting p53-mediated apoptosis and can be targeted in combination with imatinib to synergistically suppress tumor growth, providing a therapeutic strategy for treating gastrointestinal stromal tumor.
Penile indentation and hourglass deformities with Peyronie’s disease—what can we reasonably offer our patients?
Ziegelmann, Matthew , Ziegelmann, Matthew J

The Journal of Sexual Medicine | August 9, 2023 | Volume: 20 | Issue: 10 | Pages: 1230-1232

10.1093/jsxmed/qdad105 | PMID 37784214 Get It

Incidence, risk factors, and outcomes of atrial functional mitral regurgitation in patients with atrial fibrillation or sinus rhythm
Naser, Jwan A. , Lin, Grace , Scott, Christopher G. , Kennedy, Austin M , Noseworthy, Peter A. , Pellikka, Patricia A. , Nkomo, Vuyisile T. , Pislaru, Sorin V. , Scott, Christopher , Kennedy, Austin M , Noseworthy, Peter A , Pellikka, Patricia A , Nkomo, Vuyisile T , Sabbah, Michael S. , Naser, Jwan A , Michelena, Héctor I. , Lee, Eunjung

European Heart Journal - Cardiovascular Imaging | August 9, 2023 | Volume: 24 | Issue: 11 | Pages: 1450-1457

10.1093/ehjci/jead199 | PMID 37556366 Get It

Abstract Aims Atrial functional mitral regurgitation (AFMR) has been associated with atrial fibrillation (AF) and heart failure with preserved ejection fraction. However, data on incident AFMR are scarce. We aimed to study the incidence, risk factors, and clinical significance of AFMR in AF or sinus rhythm (SR). Methods and results Adults with new diagnosis of AF and adults in SR were identified. Patients with >mild MR at baseline, primary mitral disease, cardiomyopathy, left-sided valve disease, previous cardiac surgery, or with no follow-up echocardiogram were excluded. Diastolic dysfunction (DD) was indicated by ≥2/4 abnormal diastolic function parameters [mitral medial e′, mitral medial E/e′, tricuspid regurgitation velocity, left atrial volume index (LAVI)]. Overall, 1747 patients with AF and 29 623 in SR were included. Incidence rate of >mild AFMR was 2.6 per 100 person-year in new-onset AF and 0.7 per 100 person-year in SR, P < 0.001. AF remained associated with AFMR in a propensity score-matched analysis based on age, sex, and comorbidities between AF and SR [hazard ratio: 3.80 (95% confidence interval 3.04–4.76)]. Independent risk factors associated with incident AFMR were age ≥65 years, female sex, LAVI, and DD in both AF and SR, in addition to rate (vs. rhythm) control in AF. Incident AFMR was independently associated with all-cause death in both groups (both P < 0.001). Conclusions AF conferred a three-fold increase in the risk of incident AFMR. DD, older age, left atrial size, and female sex were independent risk factors in both SR and AF, while rhythm control was protective. AFMR was universally associated with worse mortality.